/
CSTL
$24.32+$0.02 (+0.08%)live
Held · Bookmarked
0 · 0
portfolios · users
Avg position size
—
of holders' portfolios
13F filers
1
institution
Market cap
$737.0M
30M shares
52-week range
$14.59 – $44.28
33% from low
Sector
SERVICES-MEDICAL LABORATORIES
Exchange
NASDAQ
CS
Borrow rate
0.38%
Easy to borrow
Price (6 mo)
Loading chart…
Change$-49.01
Valuation
Financials
Loading chart…
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.8M | $51.9M | $62.6M | $94.1M | $137.0M | $219.8M | $332.1M | $344.2M |
| Cost of revenue | $5.3M | $7.3M | $9.7M | $15.8M | $32.0M | $45.0M | $60.2M | $71.0M |
| Gross profit | $17.5M | $44.6M | $53.0M | $78.3M | $105.0M | $174.8M | $271.9M | $273.2M |
| Gross margin | 76.8% | 85.9% | 84.5% | 83.2% | 76.6% | 79.5% | 81.9% | 79.4% |
| R&D | $4.9M | $7.4M | $13.3M | $29.6M | $44.9M | $53.6M | $52.0M | $51.9M |
| Operating income | −$3.8M | $7.3M | −$6.5M | −$40.1M | −$72.9M | −$68.0M | $8.7M | −$42.8M |
| EBITDA | −$3.8M | $10.3M | −$7.1M | −$36.6M | −$58.3M | −$45.0M | $38.1M | $11.3M |
| Net income | −$6.4M | $5.3M | −$10.3M | −$31.3M | −$67.1M | −$57.5M | $18.2M | −$24.2M |
| Net margin | -27.9% | 10.2% | -16.4% | -33.3% | -49.0% | -26.1% | 5.5% | -7.0% |
| EPS (diluted) | -0.60 | -0.21 | -0.54 | -1.24 | -2.58 | -2.14 | 0.62 | -0.83 |
Annual figures · source: Financial Modeling Prep
Analyst estimates (consensus)
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $353M | $-1.46 | $-1.48–$-1.45 | 6 |
| 2027 | $393M | $-0.93 | $-0.95–$-0.92 | 6 |
| 2028 | $435M | $-0.50 | $-1.21–$0.09 | 5 |
| 2029 | $470M | $0.32 | $0.32–$0.32 | 1 |
Forward consensus · source: Financial Modeling Prep
Peer comparison
Castle Biosciences, Inc. Common Stock
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.
www.castlebiosciences.com- Employees
- 942
- IPO / List date
- Jul 25, 2019
- HQ
- FRIENDSWOOD, TX
Held by traders on TradeandTell
No one on the platform currently holds CSTL.
Super investors & insiders
Institutions holding (13F)
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 532,800 | $13.1M |
Insider activity (SEC Form 4)
Recent trades on TradeandTell
No one on the platform has traded CSTL yet.
